Press release
Fallopian Tube Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Fallopian Tube Cancer Pipeline
Explore our latest breakthroughs in Fallopian Tube Cancer Research. Learn more about our innovative pipeline today! @ Fallopian Tube Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Fallopian Tube Cancer Pipeline Report
• June 2024:- Imunon- A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
• June 2024:- ImmunoGen, Inc.- Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
• June 2024:- Incyte Corporation- A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors. This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
• DelveInsight's Fallopian Tube Cancer pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Fallopian Tube Cancer treatment.
• The leading Fallopian Tube Cancer Companies such as ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics are notable companies in the pharmaceutical and biotechnology sectors.
• Promising Fallopian Tube Cancer Therapies such as Bevacizumab, Mirvetuximab soravtansine, Pembrolizumab, Topotecan, RC88, Rucaparib, ZEN003694, Talazoparib, KAND567, and others.
Stay informed about the cutting-edge advancements in Fallopian Tube Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Fallopian Tube Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fallopian Tube Cancer Emerging Drugs Profile
• Mirvetuximab Soravtansine: ImmunoGen
Mirvetuximab Soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4. It is currently in phase III stage of development and is being developed by Immunogen.
• Tisotumab vedotin: Genmab/Seagen
Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody-drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors. Tisotumab vedotin is being developed in collaboration with Genmab. It is composed of Genmab's human monoclonal antibody (mAb) that binds to TF and Seagen's ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). It is currently in phase III stage of development.
• Pembrolizumab: Merck & Co.
Keytruda (pembrolizumab) is a drug developed by Merck used in cancer therapy. It is a monoclonal antibody, a protein that binds to specific ligands, which increases the ability of the immune system to help detect and fight tumor cells. Keytruda has already been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancers including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer, Fallopian tube cancer and several other potential disease.
Learn more about Fallopian Tube Cancer Drugs opportunities in our groundbreaking Fallopian Tube Cancer Research and development projects @ Fallopian Tube Cancer Unmet Needs- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Fallopian Tube Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Fallopian Tube Cancer Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Discover the latest advancements in Fallopian Tube Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Fallopian Tube Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Fallopian Tube Cancer Pipeline Report
• Coverage- Global
• Fallopian Tube Cancer Companies- ImmunoGen, Janssen Research & Development, OncXerna Therapeutics, Merck & Co, Alkermes plc, SOTIO a.s., Jiangsu HengRui Medicine, Advenchen Laboratories, LLC, OncoQuest, Medivation, Pfizer, Glycotope, Array Pharma/Celgene, Astex Pharmaceuticals, Lee's Pharmaceutical, Genmab/Seagen, CSPC ZhongQi Pharmaceutical Technology, Zenith Epigenetics, AiVita Biomedical, Eli Lilly and Company, Xencor Inc., Syndax Pharmaceuticals, ImmunoVaccine Technologies, Celsion, APIM Therapeutics, Regeneron Pharmaceuticals, Artios Pharma Ltd, Sumitomo Dainippon Pharma Oncology, Compugen, Exelixis, Green3Bio, Inc., OncoMed Pharmaceuticals, Transgene, and Tmunity Therapeutics are notable companies in the pharmaceutical and biotechnology sectors.
• Fallopian Tube Cancer Therapies- Bevacizumab, Mirvetuximab soravtansine, Pembrolizumab, Topotecan, RC88, Rucaparib, ZEN003694, Talazoparib, KAND567, and others.
• Fallopian Tube Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Fallopian Tube Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Fallopian Tube Cancer Pipeline on our website @ Fallopian Tube Cancer Drugs and Companies- https://www.delveinsight.com/sample-request/fallopian-tube-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Fallopian Tube Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Fallopian Tube Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Fallopian Tube Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Mirvetuximab Soravtansine: ImmunoGen
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Gimatecan: Lee's Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. TG4050: Transgene
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Fallopian Tube Cancer Key Companies
20. Fallopian Tube Cancer Key Products
21. Fallopian Tube Cancer- Unmet Needs
22. Fallopian Tube Cancer- Market Drivers and Barriers
23. Fallopian Tube Cancer- Future Perspectives and Conclusion
24. Fallopian Tube Cancer Analyst Views
25. Fallopian Tube Cancer Key Companies
26. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fallopian Tube Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3557194 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Fallopian
Fallopian Tube Cancer Market Size And Global Industry Forecast 2034
Introduction
The fallopian tube cancer market-though focused on a rare gynecological cancer-is gaining attention due to increasing diagnosis rates and expanding therapeutic options. Caused by malignant growth in the fallopian tubes, this condition carries significant clinical challenges given its often late detection and symptom overlap with ovarian cancers. As targeted therapies and diagnostics evolve, this market is emerging as a critical frontier in women's oncology.
Download Full PDF Sample Copy of Market…
Fallopian Tube Cancer Therapeutics Market: Emerging Trends and Growth Forecast t …
The global Fallopian Tube Cancer Therapeutics market was valued approximately $8.7 billion in 2023 and is projected to reach around $14.5 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 15.3% during the forecast period.
Fallopian Tube Cancer Therapeutics Market Overview
Fallopian tube cancer, a rare gynecological malignancy, has garnered increased attention due to advancements in diagnostic techniques and a deeper understanding of its pathogenesis. The market's growth…
Fallopian Tube Cancer Market Size 2023: Epidemiology, Industry Trends and Foreca …
IMARC Group has recently released a report titled "Fallopian Tube Cancer Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the fallopian tube cancer market size, latest trends, and growth forecast. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market scenario,…
Fallopian Tube Cancer Market Development, Trends, Segmentations Analysis
Global Fallopian Tube Cancer Market: Overview
The global market for fallopian tube cancer has been expanding alongside advancements in the domain of cancer research and development. The field of oncology has set on a spree of research advancements over the past decade. This trend is projected to result in development of improved cancer treatments and new avenues for seamless research. There have been several advancements in the field of women's…
Fallopian Tube Cancer Therapeutics Market Challenging Health Concerns 2028 | Pre …
Global Fallopian Tube Cancer Therapeutics Market: Overview
Fallopian tube cancer is a type of rare cancer that is only found in females. This type of cancer accounts for nearly 1 to 2 percent of all the gynecologic cancers. Since last several years, chemotherapy has been the only therapy available for the treatment of fallopian tube cancer. However, chemotherapy has several adverse side effects on health. Additionally, it also unable to offer…
Fallopian Tube Cancer Market report provide Exact forecast to 2027
The Fallopian Tube Cancer Market report offers a deep analysis of the Fallopian Tube Cancer trade. It demonstrates a quick outline of trade knowledge and key Information like Key Manufacturers , Types, Application, Table Of Content, etc of the market. The report highlights Top Venders from the worldwide and Fallopian Tube Cancer Market along with their worth of the Industry to see their progress. The worldwide Fallopian Tube Cancer analysis…
